A new document was published on the National Institute of Health website that describes the danger and ethical concerns that informed consent for ADE are not being shared with people receiving the Covid vaccines. ADE is antibody-dependent enhancement.
ADE is possible with the vaccines and it is serious enough to justify a separate clearly defined warning for all those receiving the vaccines. Quite simply, it could increase the severity of the disease by rendering the antibodies useless against the virus.
Dr. Bhakdi describes how ADE will affect the immune response of the vaccinated.
Results of the study
COVID‐19 vaccines designed to elicit neutralising antibodies may sensitize vaccine recipients to more severe disease than if they were not vaccinated. Vaccines for SARS, MERS and RSV have never been approved, and the data generated in the development and testing of these vaccines suggest a serious mechanistic concern: that vaccines designed empirically using the traditional approach (consisting of the unmodified or minimally modified coronavirus viral spike to elicit neutralising antibodies), be they composed of protein, viral vector, DNA or RNA and irrespective of delivery method, may worsen COVID‐19 disease via antibody‐dependent enhancement (ADE). This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVID‐19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials.
The prior evidence that vaccine‐elicited, antibody‐dependent enhancement (ADE) of disease is likely to occur to some degree with COVID‐19 vaccines is vertically consistent from controlled SARS studies in primates to clinical observations in SARS and COVID‐19. Thus, a finite, non‐theoretical risk is evident in the medical literature that vaccine candidates composed of the SARS‐CoV‐2 viral spike and eliciting anti‐SARS‐CoV‐2 antibodies, be they neutralising or not, place vaccines at higher risk for more severe COVID‐19 disease when they encounter circulating viruses.
The author highlights the point that this risk must be clearly presented to the recipient to fulfill the proper intent of informed consent.
Please read the entire study and share with others. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645850/